News Release Details

• Multi-year investment will support growth of contract development and manufacturing capabilities

GAITHERSBURG, Md., June 07, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finish facility located in Baltimore, Md. The multi-year expansion is expected to be completed in 2021, and will significantly increase the company’s contract development and manufacturing capacity, redundancy, and flexibility. This expansion is also anticipated to create up to 60 new jobs in the next three years.

“The expansion of our Camden facility is a significant and impactful capital investment that will generate measurable benefits for our clients,” said Sean Kirk, senior vice president, manufacturing operations and CDMO business unit head. “This investment in innovative and flexible technology not only expands our customer-centric offerings to support future growth, but also builds upon our history of quality to help ensure the utmost focus on patient safety in pursuit of our corporate mission – to protect and enhance life.”

A highlight of the multi-stage project includes the addition of a new isolator enclosed fill line. Emergent has partnered with Groninger & Co. to install their FlexPro 50 filler with isolator technology and an integrated Christ lyophilizer. This entirely new line will have the capability of filling vials, syringes and cartridges in a new fill suite with dedicated utilities. The company will also be adding a second autoclave to provide manufacturing redundancy and increased sterilization capacity, a new cold storage space to support 2-8⁰c and -20⁰c requirements, new stability chambers, new media fill incubators, and additional warehousing and office space.

“Emergent has a proven track record as a world-class provider of contract manufacturing services for both bulk drug substances and sterile injectable drug products,” said BJ Hull, vice president, general manager and site head at the Camden facility. “This $50 million investment further demonstrates our commitment to meeting and exceeding the expectations of our customers as well as to stimulating economic growth and creating jobs in Baltimore.”

“The expansion of Emergent BioSolutions’ Camden fill/finish facility is a testament to Maryland’s leadership in biotechnology,” said Congressman John Sarbanes (D-MD-03). “This facility will not only bring jobs to our community and boost our local economy, but also propel new medical advancements that will improve public health across the country.”

ABOUT EMERGENT BIOSOLUTIONS INC.
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, prospects, plans, objectives, and any other statements containing the words "will," "believes," "expects," "anticipates," "intends," "plans," "targets," "forecasts," "estimates" and similar expressions in conjunction with, among other things, discussions about the anticipated benefits of the expansion of the Camden fill/finish facility, and the timing of the completion of such expansion are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including the amount of time it takes to complete the buildout of our Camden facility and obtain regulatory approvals needed to complete planned improvements to the facility, our ability to secure and maintain contracts sufficient to utilize the full potential of the expanded facility and our manufacturing capabilities and strategy. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com

Emergent BioSolutions